These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9916651)

  • 21. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.
    Jantunen E; Itälä M; Juvonen E; Leppä S; Keskinen L; Vasala K; Remes K; Wiklund T; Elonen E; Nousiainen T
    Bone Marrow Transplant; 2006 Feb; 37(4):367-72. PubMed ID: 16415893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
    McCoy AG; Smith EP; Atkinson ME; Baranski B; Kahl BS; Juckett M; Mitchell T; Gangnon R; Longo WL
    Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
    Popat U; Hosing C; Saliba RM; Anderlini P; van Besien K; Przepiorka D; Khouri IF; Gajewski J; Claxton D; Giralt S; Rodriguez M; Romaguera J; Hagemeister F; Ha C; Cox J; Cabanillas F; Andersson BS; Champlin RE
    Bone Marrow Transplant; 2004 May; 33(10):1015-23. PubMed ID: 15048145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation].
    Wang AL; He ZD; Luo Y; Xiao LX; Liu XY; Zhu YH
    Ai Zheng; 2003 Dec; 22(12):1317-20. PubMed ID: 14693059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma.
    Paltiel O; Rubinstein C; Or R; Nagler A; Gordon L; Deutsch L; Polliack A; Naparstek E
    Bone Marrow Transplant; 2003 Apr; 31(7):565-9. PubMed ID: 12692622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome.
    Kumar L; Ganessan P; Ghosh I; Panda D; Gogia A; Mandhania S
    Natl Med J India; 2010; 23(6):330-5. PubMed ID: 21561042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.
    Salar A; Sierra J; Gandarillas M; Caballero MD; Marín J; Lahuerta JJ; García-Conde J; Arranz R; León A; Zuazu J; García-Laraña J; López-Guillermo A; Sanz MA; Grañena A; García JC; Conde E;
    Bone Marrow Transplant; 2001 Feb; 27(4):405-12. PubMed ID: 11313670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
    Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
    Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease.
    Lin TS; Avalos BR; Penza SL; Marcucci G; Elder PJ; Copelan EA
    Bone Marrow Transplant; 2002 May; 29(9):763-7. PubMed ID: 12040474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating stem cell autograft in malignant lymphomas.
    Majolino I; Scimè R; Indovina A; Vasta S; Fabbiano F; Magrin S; Hauser D; Gentile S; Santoro A; Felice R
    Haematologica; 1990; 75 Suppl 1():74-8. PubMed ID: 1972133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.